Volume: 43 Issue: 2
Year: 2023, Page: 735-741, Doi: https://doi.org/10.51248/.v43i02.2700
Introduction and Aim: Gaucher disease (GD) is an autosomal recessive ailment caused due to mutations in the GBA1 gene, encoding for the lysosomal enzyme, glucocerebrosidase. The aim was to evaluate the clinical, biochemical, and molecular parameters associated with this disease, as well as to identify symptoms and covariables thought to be most diagnostic of early GD presentation, allowing for early diagnosis and management.
Methodology: This cross-sectional study involved twenty-six patients diagnosed with GD at the Metabolic Department of Central Child Teaching Hospital, Baghdad, Iraq. Diagnosis depended mainly on history and physical examination and confirmed by beta-glucosidase enzyme assay of dry blood spot on filter paper and Lyso-GL-1 level. Amplification-based next generation sequencing approach was used in investigating the GBA1 gene at the molecular level.
Results: The mean age of the 26 (17 male and 9 female) patients was 9.13 years, with 100% consanguinity and 50% positive family history. The average number of years from the start of clinical manifestations to the diagnosis' validation was 3.82 years. The original age of presentation was 2.83 years, and the initial age of diagnosis was 6.65 years. Hepatosplenomegaly (85%), pallor (88%), splenomegaly (12%), splenectomy (12%), hemorrhage (19%), bone discomfort (23%), bone breakage (12%), and GD type III (19%) were observed. Among patients 65% exhibited radiological bone abnormalities, 54% had Erlenmeyer flask deformity, and 1.5% had osteopenia and fracture. Studies of GBA1 gene showed the mutation C.[1448T>c ](P.[ Leu483Pro] to be the most common. Hepatosplenomegaly and hematological deficiencies were effectively improved by enzyme replacement therapy.
Conclusion: In Gaucher disease, GBA1 gene mutation analysis could provide some predictive information about disease variance as well as severity. PCV%, platelet count, ferritin, and lyso-GL-1 levels could be employed as biomarkers for the diagnosis of GD. ERT proved effective in treating hematological and hepatosplenomegaly abnormalities.
Keywords: Gaucher disease (GD); Enzyme replacement therapy (ERT); Lysosomal storage disorders (LSDs); glucosidase beta acid (GBA1) gene
1. Huang, W.J., Zhang, X., Chen, W.W. Gaucher disease: A lysosomal neurodegenerative disorder. Eur Rev Med Pharmacol Sci. 2015; 19(7):1219-1226.
2. Orvisky, E., Park, J.K., LaMarca, M.E., Ginns, E.I., Martin, B.M., Tayebi, N., et al., Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab. 2002;76(4):262-270.
3. Mikosch, P., Hughes, D. An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr. 2010;160(23-24):609-624.
4. Hruska, K.S., LaMarca, M.E., Scott, C.R., Sidransky, E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008; 29(5):567-583.
5. Linari, S., Castaman, G. Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab. 2015; 12(2):157-164.
6. Mistry, P.K., Belmatoug, N., Vom, D. S., Giugliani, R. Understanding the natural history of Gaucher disease. Am J Hematol. 2015 Jul; 90 Suppl 1: S6-S11.
7. Grabowski, G.A. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008;372(9645):1263-1271.
8. Stirnemann, J., Vigan, M., Hamroun, D., Heraoui, D., Rossi-Semerano, L., Berger, M.G., et al., The French Gaucher's disease registry: clinical characteristics, complications, and treatment of 562 patients. Orphanet J Rare Dis. 2012;7:77.
9. Verma, J., Thomas, D.C., Sharma, S., Jhingan, G., Singh, A., Hsiao, K.J., et al., Inherited metabolic disorders: Quality management for laboratory diagnosis. Clin Chim Acta. 2015 Jul 20;447:1-7.
10. Ankleshwaria, C., Mistri, M., Bavdekar, A., Muranjan, M., Dave, U., Tamhankar, P., et al., Novel mutations in the glucocerebrosidase gene of Indian patients with Gaucher disease. J Hum Genet. 2014; 59(4):223-228.
11. Deegan, P.B., Moran, M.T., McFarlane, I., Schofield, J.P., Boot, R.G., Aerts, J.M., et al., Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005; 35(2):259-267.
12. Mistry, P.K., Cappellini, M.D., Lukina, E., Ozsan, H., Mach, S., Rosenbaum, H., et al., A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110-115.
13. Mistry, P.K., Lukina, E., BenTurkia, H., Shankar, S.P., Baris, H., Ghosn, M., et al., Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial. Am J Hematol. 2017;92(11):1170-1176.
14. Beutler, E., Grabowski, G.A. Gaucher disease. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., Eds., The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, 2001; 3635-3668.
15. Chiong, M.A.D., Racoma, M.J.C., Abacan, M.A.R. Genetic and clinical characteristics of Filipino patients with Gaucher disease. Mol Genet Metab Rep. 2018;15:110-115.
16. Alasmar, D. Gaucher disease in Syrian children: common mutations identification, and clinical futures. Ann Saudi Med. 2015; 35(2):127-132.
17. El-Morsy, Z., Khashaba, M.T., Soliman, Oel-S., Yahia, S., El-Hady, D.A. Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes. World J Pediatr. 2011;7(4):326-330.
18. Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., et al., A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci. 2017;18(2):441.
19. Alfonso, P., Aznarez, S., Giralt, M., Pocovi, M., Giraldo, P. Spanish Gaucher’s Disease Registry. Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet. 2007; 52(5):391-396.
20. DeMayo, R.F., Haims, A.H., McRae, M.C., Yang, R., Mistry, P.K. Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease. AJR Am J Roentgenol. 2008;191(1):115-123.
21. Stein, P., Yu, H., Jain, D., Mistry, P.K. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol. 2010; 85(7):472-476.
22. Mistry, P., Germain, D.P. Phenotype variations in Gaucher disease. Rev Med Interne. 2006; 27 Suppl 1: S3-S10.
23. Rolfs, A., Giese, A.K., Grittner, U., Mascher, D., Elstein, D., Zimran, A., et al., Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One. 2013; 8(11):e79732.
Ikhlas Ali Ahmed, Alaa Abbas Fadhel. A reappraisal of Gaucher disease patients - Clinical presentation, and diagnosis in rare disease unit of central child teaching hospital in Baghdad province. Biomedicine: 2023; 43(2): 735-741